Abstract | AIMS: This subgroup analysis of the A₁chieve study examined data from 15,545 people who started treatment with insulin detemir ± oral glucose-lowering drugs in routine clinical care. METHODS: RESULTS: HbA₁c for the global cohort improved after 24 weeks from 9.5 ± 1.6% by -2.0 ± 1.6% [80 ± 17 by -22 ± 17 mmol/mol] (-2.1 ± 1.6% [-23 ± 17 mmol/mol] for insulin-naïve participants; -1.6 ± 1.7% [-17 ± 19 mmol/mol] for prior insulin users). Fasting plasma glucose and postprandial plasma glucose were also significantly reduced (p<0.001), irrespective of prior therapy or geographical region. The incidence of major hypoglycaemia decreased significantly over 24 weeks in both the insulin-naïve and insulin-experienced groups (p<0.0001). Mean body weight decreased overall by -0.4 ± 4.0 kg and blood pressure, lipid profiles, and self-reported quality of life improved over 24 weeks for all people starting treatment with insulin detemir. CONCLUSION: People with type 2 diabetes in poor glycaemic control starting treatment with insulin detemir reported significant improvements in glycaemic control with improved treatment tolerability, irrespective of prior treatment and geographical region, after 24 weeks.
|
Authors | Alexey Zilov, Nabil El Naggar, Siddharth Shah, Chunduo Shen, Jihad Haddad |
Journal | Diabetes research and clinical practice
(Diabetes Res Clin Pract)
Vol. 101
Issue 3
Pg. 317-25
(Sep 2013)
ISSN: 1872-8227 [Electronic] Ireland |
PMID | 24119589
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2013. Published by Elsevier Ireland Ltd. |
Chemical References |
- Glycated Hemoglobin A
- Insulin, Long-Acting
- Insulin Detemir
|
Topics |
- Diabetes Mellitus, Type 2
(drug therapy, metabolism)
- Female
- Glycated Hemoglobin
(metabolism)
- Humans
- Insulin Detemir
- Insulin, Long-Acting
(therapeutic use)
- Male
- Middle Aged
- Prospective Studies
- Treatment Outcome
|